Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...
Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli ...
New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.
INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced today that the companies ...
Hosted on MSN1mon
Samsung Biologics inks $668m manufacturing deal with European pharmaIn July 2024, Samsung Bioepis received US Food and Drug Administration (FDA) approval for Epysqli (eculizumab-aagh), a biosimilar to AstraZeneca acquiree Alexion Pharmaceuticals’ Soliris ...
EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback